Top Markets
#1 Audiera Audiera +35.09%
#2 GALA GALA +33.70%
#3 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +32.94%
#4 Bitcoin Cash Bitcoin Cash +32.75%
#5 Fabric Protocol Fabric Protocol +32.18%
#6 Tutorial Tutorial +30.33%
#7 Zora Zora +29.59%
#8 Bless Bless +29.29%
#9 Arowana Arowana +28.17%
#10 Pepe Pepe +26.40%
Coin of the day
Audiera Audiera
設定
言語
日本
通貨
USD
テーマ
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
株式のランク #24577
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
株価
$1.48
最終同期: 2025-03-24
時価総額
$59.05M
変化（1日）
0.00%
変化（1年）
0.00%
国
GB
取引 Achilles Therapeutics plc (ACHL)

カテゴリー

Healthcare
Achilles Therapeutics plc（ACHL）の利益
2026 時点の利益 TTM: 0
Achilles Therapeutics plc の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Achilles Therapeutics plc の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH